Alendronate 70 mg once weekly vs. placebo: Tolerability study in patients with osteoporosis.

被引：0
作者：
Greenspan, SL
Field-Munves, EM
Tonino, RP
Mako, B
Smith, ME
Yates, J
Palmisano, J
机构：
[1] Oteoporosis Prevent & Treatment Ctr, Pittsburgh, PA USA
[2] Springhouse Profess Ctr, Allentown, PA USA
[3] Good Hlth, Burlington, VT USA
[4] Merck & Co Inc, W Point, PA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S405 / S405
页数：1
相关论文
共 50 条
  • [41] Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
    Uchida, S
    Taniguchi, T
    Shimizu, T
    Kakikawa, T
    Okuyama, K
    Okaniwa, M
    Arizono, H
    Nagata, K
    Santora, AC
    Shiraki, M
    Fukunaga, M
    Tomomitsu, T
    Ohashi, Y
    Nakamura, T
    JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (05) : 382 - 388
  • [42] Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
    Emkey, Ronald
    Delmas, Pierre D.
    Bolognese, Michael
    Borges, Lindolfo C.
    Cosman, Felicia
    Ragi-Eis, Sergio
    Recknor, Christopher
    Zerbini, Cristiano A.
    Neate, Colin
    Sedarati, Farhad
    Epstein, Solomon
    CLINICAL THERAPEUTICS, 2009, 31 (04) : 751 - 761
  • [43] Upper gastrointestinal tolerability of alendronate 70 mg once-weekly with concomitant use of NSAIDs compared to coxibs.
    de Papp, AE
    Wang, L
    Petruschke, RA
    Geba, GP
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S85 - S85
  • [44] Balto I: Patient preference and convenience study of once-monthly ibandronate versus once-weekly alendronate for the treatment of osteoporosis.
    Emkey, R
    Binkley, N
    Seidman, L
    Rosen, C
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S296 - S296
  • [45] Safety of once-weekly alendronate 70 mg in peridontal disease.
    Van Dyke, T
    Ryder, M
    Cordero, R
    Gallagher, A
    Griffiths, GR
    Offenbacher, S
    Cizza, G
    Shih, W
    Kimberlin, M
    Meng, L
    Lombardi, A
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S198 - S198
  • [46] Once-weekly alendronate 70 mg: Sustained suppression of bone resorption
    Bone, H
    Schnitzer, T
    Reid, I
    Adami, S
    Miller, P
    Kaur, A
    Snodgrass, S
    Santora, A
    Orloff, J
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S29 - S29
  • [47] Safety of once-weekly alendronate 70 mg in periodontal disease.
    Van Dyke, T
    Ryder, M
    Cordero, R
    Gallagher, A
    Griffiths, G
    Offenbacher, S
    Cizza, G
    Kimberlin, M
    Lombardi, A
    Meng, L
    Shih, W
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2001, 10 (04): : 404 - 404
  • [48] Oral alendronate 70 mg once weekly is not associated with endoscopic upper GI mucosal lesions compared to placebo.
    Lanza, F
    Sahba, B
    Schwartz, H
    Torosis, J
    Winograd, S
    Quan, H
    Reyes, R
    Leung, A
    Daifotis, A
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S198 - S198
  • [49] Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis (vol 20, pg 2031, 2004)
    Sebba, AI
    Bonnick, SL
    Kagan, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 325 - 325
  • [50] The effect of a once-weekly tablet containing alendronate and vitamin D3 for the treatment of osteoporosis.
    Lips, PT
    Recker, RR
    Rosen, CJ
    Bone, H
    Minne, HW
    Callahan, G
    Lamotta, A
    He, W
    Santora, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S396 - S397
12345